Skip to Main Content

Paper Details

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Journal of Antimicrobial Chemotherapy
101
2014
GS-7340, HIV, HIV reverse transcriptase, HIV-1, HIV-1 RNA, Tenofovir alafenamide, flatulence, headache, inside cells, nausea, nucleotide, peripheral blood mononuclear cells, tenofovir, tenofovir alafenamide, tenofovir disoproxil fumarate
Author NameAffiliation
Martin MarkowitzAaron Diamond AIDS Research Center, The Rockefeller University Hospital
  • 1 - 1

Datasets

Release 1.2